Language selection

Search

Patent 1049405 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent: (11) CA 1049405
(21) Application Number: 1049405
(54) English Title: TEST METHOD TO DETERMINE PULMONARY EMBOLISM
(54) French Title: METHODE DE DIAGNOSTIQUE DE L'EMBOLIE PULMONAIRE
Status: Term Expired - Post Grant Beyond Limit
Bibliographic Data
Abstracts

English Abstract


A B S T R A C T
Detection of an antigen in circulating blood which
is normally present in the lung signals the presence of
pulmonary thromboembolism.


Claims

Note: Claims are shown in the official language in which they were submitted.


THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A method for determining the presence of a
pulmonary embolism in a human which comprises utilizing
human lung tissue to stimulate the production of an antibody
in animal serum, absorbing said serum with normal human
serum to remove extraneous antibodies, separating resulting
antiserum, incubating said antiserum with human serum to
be tested and determining the positive presence of a pul-
monary embolism by the occurrence of an immunological
reaction.
2. A test method as in Claim 1 wherein the immuno-
logical reaction is a precipitin reaction.
3. A test method as in Claim 2 wherein the reac-
tion is identified by microimmunodiffusion.
4. A test method as in Claim 2 wherein the reac-
tion is identified by macroimmunodiffusion.
5. A test method as in Claim 2 wherein the reac-
tion is identified by electrophoresis.
6. A test method as in Claim 1 wherein the animal
is a rabbit.
7. A test method for determining the presence of
a pulmonary embolism in a human which comprises incubating
human serum to be tested with an antiserum containing an
antibody produced in animal serum by stimulation with an
antigen contained in human lung tissue and determining the
positive presence of a pulmonary embolism by the occurrence
of an immunological reaction.
- 12 -

8. A test method as in Claim 7 wherein the immuno-
logical reaction is a precipitin reaction.
9. A test method as in Claim 8 wherein the reac-
tion is identified by microimmunodiffusion.
10. A test method as in Claim 8 wherein the reac-
tion is identified by macroimmunodiffusion.
11. A test method as in Claim 8 wherein the reac-
tion is identified by electrophoresis.
12. A test method as in Claim 7 wherein the animal
is a rabbit.
13. A test method as in Claim 7 wherein the anti-
serum is preabsorbed with normal human serum prior to incu-
bation with the serum to be tested.
14. An antibody preparation containing an antibody
reactive with the antigen normally present in human lung
tissue which appears in the serum of humans afflicted with
pulmonary embolism.
15. An antigen which is a protein having an
apparent molecular weight of about 210,000, being negatively
charged in aqueous media, having an isoelectric point above
5, giving a single coomasie blue staining band in polyacryla-
mide electrophoresis, being free of lipid or carbohydrate
segments; the said antigen being further characterized by an
ability to stimulate antibody production in animal serum so
as to produce an antiserum which when incubated with serum
from a human afflicted with pulmonary embolism will indicate
the presence of the said embolism by the occurrence of an
immunological reaction.
- 13 -

16. A test method as in Claim 1 wherein the
reaction is identified by radioimmunoassay.
17. A test method as in Claim 7 wherein the
reaction is identified by radioimmunoassay.
- 14 -

Description

Note: Descriptions are shown in the official language in which they were submitted.


49~5
BACKGROUND O~ INVENTION
Pulmonary thromboembolism is a highly prevalent
disease associated with repetitive episodes of increasing
peril, and is one of the leading causes of death. While
prompt recognition is crucial since rational and frequently
effective therapy is available, clinical diagnosis is difficult
; and frequently incorrect. There is a need for a diagnostic
indicator which is available on a larger scale than present
radiologic methods which not infrequently are indeterminate.
~uch a diagnostic indicator could serve both as a screening
method and also to complement information from radiologic
methods. Since recognition of pulmonary thromboembolism is
a major medical problem world-wide, a simple screening test
j for it would have widespread use and impact in medical manage-
ment of the probleM.
It has now been discovered that the presence of an
antigen in human serum provides a safe, reliable and effective
basis for confirming the presence of pulmonary embolisms.
THE INVENTION
An antigen which is normally found in human lungs
spills over into blood serum in the presence of a pulmonary
embolism. The antigen can be used to stimulate the production
of an antibody in animal blood. The antibody, in turn, can
be used to detect the presence of the antigen in serum, thereby
confirming the existence of the pulmonary embolism.
The invention therefore, comprises a test method for
determininy the presence of a pulmonary embolism in a human
by irst utilizing normal lung tissue to stimulate the
production of an antibody in animal serum, and thereafter
incubating the serum containing the antibody with the human
serum to be tested. The positive presence of a pulmonary
2 ~
. .

D4~ 5
embolism is signaled by the occurrence of an immunological
reaction.
In accordance with one aspect of this invention,
there is provided a method for determining the presence of a
pulmonary embolism in a human which comprises utili~ing human
lung tissue to stimulate the production of an antibody
animal serum, absorbing said serum with normal human serum to
remove extraneous antibodies, separating resulting antiserum,
incubating said antiserum with human serum to be tested and
determining the positive presence of a pulmonary embolism by
the occurrence of an immunological reaction.
In accordance with a further aspect of this invention, :
there is provided a test method for determining the presence of
;a pulmonary embolism in a human which comprises incubating human
serum to be tested with an antiserum containing an antibody
produced in animal serum by stimulation with an antigen contained
in human lung tissue and determining the positive presence of a
pulmonary embollsm by the occurrence of an immunological reaction.
In accordance with yet a further embodiment of this
invention, there is provided an antibody preparation containing an
antibody reactive with the antigen normally present in human lung
tissue which appears in the serum of humans afflicted with
pulmonary embolism.
In a further embodiment of this invention, there is
. provided an antigen which is a protein having an apparent
molecular weight of about 210,000, being negatively charged
in aqueous media, having an isoelectric point above 5, giving a
single coomasie blue staining band in polyacrylamide
electrophoresis, being free of lipid or carbohydrate segments;
the said antigen being further characteri~ed by an ability to
~ ~ - 2a -
,
:,' ~
3~ ~

~4~4~5
stimulate antibody production in animal serum so as to produce
an antiserum which when incubated with serum from a human
afflicted with pulmonary embolism will indicate the presence
of the said embolism by the occurrence of an immunological
reaction.
!
'', , :.
~ 2b -
- . : ,, ~ , . . . . .

~ 94~5
Isolation of ~nti~en Compositions and Preparation of Antibod
Y.
While substantially any animal can b~ em~loyed for
the production o~ antibody, as is the case witn such pro-
cedures, for convenience the procedure will be described as
applied to the utilization of a rabbit. Those s~illed in the
art will recognize that larger animals such as goats, horses
and cattle can be similarly employed; and, in fact, would be
employed for production of large amounts of antibod~.
Lung washings were prepared by first extracting 50
to 100 gram samples of normal human lung with isotonlc saline
(0.85% aqueous NaCl~. The lung had been ob.ained following
surgical remo~al for carcinoma. Four e~tracts o about 50 ml
each were lyophilized and redissolved in about 10 ml of isotonic
saline and applied to a Sephadex G-200 col~n having a 2.5 cm
diameter and a bed volume of 260 ml. Ten ml fractions were
collected at a flow rate of 10 ml/hr at a te~perature of 16C.
.
The column was developed with 0.1M Tris-Cl, pH 7.4-lM NaCl.
Fractions were assayed for their absorbance at 280 nm, a
characteristic absorbence feature of protein molecules. The
2~ initial excluded peak, the surfactant fraction, ~fractians
10-25) w~re pooled and split into 5 ml portions. One such
portion mi~ed with an equal portlon of Freund's adju~ant is
used for the development of antibody in~raboits.
,
; In an alternate method for preparing the antigen
.. . .
contalning mixture, 0.4 to 1 g portions oî numan lung similarly
obtained and held, upon removal, at 0C and thereafter at
-75~ to 85C were cut into small pieces and homogenized at
0C in 3 ml of 0.1 M potassium phosphate at p~ 7Ø An alter-
nate homogenizin~ ~ehicle is 3 ml of 0.25~ sucxose-1~1
potassium phosphate at p~7.4.
.
,
..... ~
. ~ ~ . . . -

~4~405
Homogenization is effected by grinding in a glass
tissue grinder with a motor driven Teflon pestle or in a
motor driven Lourdes stainless steel homogenizer. Additional
buffer is gradually added to increase the volume to lS ml.
The mixture is then added to an equal volume of Freund's
adjuvant and blending is continued at 0C to form a thick
creamy mixture. This suspension may be used to stimulate
antibody production.
- About 5 ml of the antigen containing medium was
injected subcutaneously into adult white male rab~its, gen-
erally at one, but sometimes up to fou~,separate sites.
Injections were repeated at about two week intervals for about
sixteen weeks. At the end of the series, the rabbits were bled
by cardiac puncture or from the ear vei~. The blood was
allowed to clot and the serum separated by centrifugation for
10 minutes at 2000 rpm.
The extraneous antibod~es in the rabbit serum are
remo~ed by absorption with the normal human serum. This was
- effected by mixing the normal human serum with the rabbit
serum ih volume ratios of from about 0.03 to 1 to 0.1 to 1
human to rabbit. The mixture is stirred at room temperature
for 30 minutes and then stored for about 16 hours at 4~. The
mixture was centrifuged at 10,000 g for 30 minutes at 4C
to precipitate the reaction products of the extraneous antigen-
antibody reactions. Since normal human serum was employed,
the desired antibody did not react, and remained in the
supexnatant. The procedure was repeated several (about 3)
times tD insure as complete remo~al as possible of poten-
tially interfering antlbodies. The flnal supernatant is used
as the testin~ composition.
,
_
.

9~s ~-
~ This testin~ composition will give an immunological
reaction when incubated with human lung supernatant (prepared
as described hereinafter), the lung surfactant fraction, or
serum ~f patients positively diagnosed by pulmonary scan
for the presence of pulmonary embolism~ It does not however
react with normal human sera. It appears then, that the
antigen is normally present in the human luny, is not normally
present in normal human sera, but does appear in the sera of
patients afflicted wit~ pulmonary embolism.
Human lung supernatant was prepared by a 90 minute
centrifugation at 100,000 g at 4C in an ultracentrifuge of
human lung ~ieces homogenlzed in a 1:1 suspension with 0.25 M
sucrose - 1 m.'~ phosphate at pH 7.4.
The antigenic preparations, that is the surfactant
fraction, isolated from the Sephadex G-200 columns can be
further purified. To do so, the surfactant fractions are
dialyzed against deionized water for 24 hours, lyophilized
and the residue dissolved in 0.1 M Tris-Cl, p~ 8.6~ One ml
of the dissolved lyophilizate is subjected to ion exchange
on a DEAE cellulose column (2.5 x 66 cm) and elu~ed at a flow
rate of 0.33 ml/min with a gradient between equal volumes of
0.1 M Tris-Cl, pH 8.6 (mixing chamber) and 0.1 M Tris-Cl,
p~ 8.6 plus l~S NaC1 (reservoir). Ten ml fractions are
collected, lyophilized and dissolved in 0.5 ml of deionized
water. A sample as small as 3 microliters will give a positive
test with rabbit antibody serum by microdifusion.
.
When human lung surfactant fraction, human lung
100,000 g supernatant and human serum from a patient positive
for pulmonary embolism ~y perfusion scan were tested against
rabbit serum antibody by standard microimmunodiffusion,
macroim~unodif~usion and electrophoresis techniques, all three
.. ...
materials indicated the presence o~ a common antigen.
~.

9~5
Microimmunodi~fusion was carri~d out by pouring onto
a plastic microscope slide 2-5 ml o 1.5~ Difco special noble
agar in 38 ~M barbital buffer, pH 8.2. Wells and troughs were
cut into the agar, The antibody preparation was addcd to the
troughs, and antigen preparations were added to the wells.
Macroimmunodiffusion was accomplished by preparing
a 100 by 1.5 cm Petri dish with an agar layer from 8 ml of
the same agar as in the micro techni~ue, and then cutting
the wells and troùghs.
Both types of diffusion were carried out by incuba-
tion at 37C for 24 to 72 hours~ The gels were washed for
about 24 hours wi~h several changes of normal saline. The
lines of precipitation were visualized by staining with 1%
amido black dye solution in water, methanol, acetic acid,
5:5:1 by volume.
Optimum concentrations of antibody and antigen
preparations were determined by varying the concentration of
antigen in welis with constant antibody in troughs. A few
simple observations of the precipitin lines is sufficient.
Immunoelectrophoresis was carried out on 7.5 by 2.5
~m glass or plastic slides. Agar buffered as in ~he dif~usion
techniques was poured and wells formed on opposite sides o
the middle. ~Antigenic preparations were placed in the wells
and electrophoresed for about 2 hours at room temperature at
a constant voltage power supply such that the potential dif~er-
ence across the slides was 4a volts. The gel slides and buffer
.
, reservoirs were connected by microporous membrane wicks. After
:i
~lectrophoresis, troughs were out out and the antibody composi-
` ~ tion or antiserum addedO Incubation and staining were as
;~ described or the`immunodiffusion procedures. The preci;piti~
. .
reaction, as evidenced by the precipitation took place on
the anode side of the startlng well. ~-

s
As is clear from the above, the antigen may be
~eparated from lung tissue by extraction. Saline or other
extractants may be employed~ It may thereafter be puri~ied
by chromatographic techniques, although it is not necessary
to do so since relatively crude suspensions of lung homogenates
can be usefully employed. Any of these lung tissue prepara-
tions can be used to stimulate antibody produc:tion~
While the principal Lmmunological reaction used to
describe the test method of this invention has been the
precipitin reaction in agar using immunodiffusion or electro-
phoresis, it is evident that other procedures can also be
employed. These include, for example, complement fixation
and hemagglutination. The antigen may also be tagged or
labeled with a detectable radioactive element such as
1 lI; I, C or S. Labeling may similarly be effected
with a fluorescent material such as fluorescein, rhodamine or
auramine, or with an enzyme such as peroxidase, ~-glucouroni-
..
dase, urease or the like. The antibody-antigen reaction can
then be detected colorimetrically or by radio counting
procedures.
: For convenience, the antigen of this invention has
been tentatively named the I~ antigen. In an electrophoretic
study of 106 patients studîed by pulmonary scan for suspended
pulmonary thromboembolism, 67~ of those diagnosed as positive
by the scan had detectable LA antigen compared to only 12 to
14% of patients with negative scan. The results may actually
be better than indicated because it is generally recognized
. ~ .
that the scan technique gives a number of false positives and
negati~es.
The following non-limiting example illustrates the
preparation of purified antigen, and the testing thereof to
,
~-~ establish certain of its chemical and physical properties,
.: ' , '
~. . . . .
~. ~- . .
., , ~
. .

~940~
An analysis of the example indicates that the antigen
is a protein with an apparent molecular weight of about 210,000,
is negatively charged in aqueous media at pH 8.2, and has an
isoelectric point above 5. In polyacrylamide gel electrophoresis,
it gives a single coomasie blue staining band. It is free of
detectable lipoprotein or glycoprotein; that is, it contains no
apparent lipid or carbohydrate segments.
The purified antigen, or antigenic preparations are
of value because when utilized to stimulate antibody production
fewer contaminating antibodies are produced so that the initial
absorption with normal human serum which is referred to above
can be omitted. Moreover, wi-th purified antigenic compositions,
a higher concentration of antibody is produced in the animal
serum. Furthermore, the sensitivity of the radioimmunoassay
test can be markedly improved.
EXAMPLE
A total of 340 g of human lung tissue at 0C was cut
into small pieces and homogenized in 4 volumes of 0.01 M Tris-
0.25 M sodium chloride at pH 7.6 in a blender for 5 minutes at
30 second intervals at 3 to 5C. The homogenate was centrifuged
at 6,000 g for 60 minutes at 5C, and the supernatan-t liquid
centrifuged for 2 hours at 45,000 g at 5C.
The resulting supernatant liquid was then subjected to
salt fractionation.
Ammonium sulfate fractionation was achieved by slow
addition of saturated ammonium sulfate with stirring at 0 to
5C to 30% saturation. The liquid was adjusted to pH 7.8 with
5Nsodium hydroxide, stirred for 2 hours, and the resulting
precipitate removed at 6,000 g. The supernatant was then brought
to 50% saturation with ammonium sulfate in the same manner, and
the precipitate recovered by centrifugation at 6,000 g for 30
minutes.
- 8 -
:` ~
: '
~ . _ _ . . _ . ... _ __ . . .

~4~
The precipitate was dissol~ed in one quarter of the
original homogenate volume of normal saline and dialyzed
e~haustively against the same solution at 4C for about 24 hours.
(The normal saline may be replaced with 0.01 M Tris-0.25 M
sodium chloride.)
The dialyzed solution was clarified by centrifugation
at 6/000 g for 60 minutes and the precipita-te discarded.
The supernatant was subjected to the exact same
procedure with 30% and 50~ ammonium sulfate followed by dialysis
and the resulting dialyzed solution adjusted to pH 3.0 by slow
addition of l N hydrochloric acid with gentle stirring during
the period of about l hour. The solution was centrifuged at
6,000 g for 60 minutes to separate insoluble precipitate which
was then discarded.
The acidified solution was brought to 50~ ammonium
sulfate saturation by slow addition of an equal volume of
saturated ammonium sulfate with constant stirring. Stirring
was continued for 2 hours, and the mixture centrifuged for one-
half hour at 6,000 g. The precipitate was dissolved in an equal
volume of 0.01 M Tris-0.25 M sodium chloride at pH 7.4. The
acidification and ammonium sulfate precipitation steps were -
repeated and the precipitate again dissolved in one-quarter the
initial volume of the Tris buffer. The solution was dialyzed
against the same solution, and centrifuged at 6,000 g for l hour
to remove the precipitate.
The solution was subjected to gel filtration on a
sepharose 6B column (2.6 by 85 cm previously equilibrated with
Tris buffer at pH 7.4), at a flow rate of 30 to 35 ml/hr. at
5C. The 2.5 ml eluted fractions were tested by immunoelectro-
phoresis -to locate LA antigen which appeared in fractions 95 to
113, and represented about 9.9% of the protein applied as
measured by absorbance at 280 nm. Protein recovery was 98.6%.
_ g _
~;
~ --- . . .

~4~ D5
The LA antigen containing fractions were pooled and
e~haustiYely dialyzed against deionized ~a~er at about ~C.
Precipitate was removed by centrifugation at 6,000 g for 1 hour.
The supernatant was dialyzed against Tris buffer, pH 7.4, and
centrifuged at 6,000 g for 1 hour to remove any precipitate.
The volume was reduced by blowing a stream of air on
the solution in a dialysis bag, and the solution subjected to
sepharose 6B column gel filtration twice. The LA antigen con-
taining fractions were identically placed in all three gel
filtrations, and were identified by immunoelectrophoresis.
The LA antigen containing fractions were pooled,
concentrated and dialyzed against 0.01 M potassium phosphate at
4C for a period of about 10 hours at pH 6. The dialyzate was
centrifuged at 6,000 g for 30 minutes. The supernatant solution
was applied to a carboxymethyl cellulose column (2 by 18 cm,
56 ml bed volume, previously cycled with 0.5 N sodium hydroxide,
water, 0.5 N hydrochloric acid, 0.5 N sodium acetate at pH 4.8
and 0.06 M sodium acetate) and equilibrated with 0.01 M potassium
phosphate buffer at pH 6. The solution was eluted stepwise with
separate fractions of 0.01 M potassium phosphate buffers at pH
6.0, the initial buffer solution being free of sodium chloride,
and subsequent solutions containing respectively 0.05 M, 0.1 M,
0.15 M and 0.2 M sodium chloride. The eluted fractions (each
2.5 ml) were analyzed by immunoelectrophoresis, and the LA
antigen was found in the fractions containing 0.15 M sodium
chloride. (Immunoelectrophoresis here and in the previously
described analyses was carried out using rabbi~ antihuman lung
antiserum.)
The fractions containing the antigen were pooled,
reduced in volume, and dialyzed against 0.01 M potassium phos-
ce~tri f~.
phate at pH 6.8. The diaLyzate was ~ to remove precipitate~
~, -- 1 0 --
. I , ~
:', .
.

- ` 1(1 9~9LC~5
The supernatant solution ~as applied to an 0.8 by
15 c~ ~rushite-hydroxyapatite colume (Analy-tical Biochemistry
59 16-23, 1974~ previously equilibrated with 0~01 M potassium
phosphate at pH 6.8, and eluted stepwise with 0.01, 0.1, 0.2 and
O.4 M po-tassium phosphate at pH 6.8. Fractions (2.5 ml) were
tested by immunoelectrophoresis as previously described. The
LA antigen was located in the fractions eluted with 0.2 M
potassium phosphate.
The fractions were pooled, reduced in volume, and
dialyzed against Tris buffer at pH 7.4 at 4C for about 10 hours.
The LA antigen in the dialyzate was analyzed. It is
a protein which reacts immunologically with rabbit antihuman lung
antiserum. Its molecular weight by sepharose 6B fil-tration is
approximately 210,000. Upon polyacrylamide gel electrophoresis
~r s~ 9 nn~1s
/ by the method of Ornstein and Davis (An-a~ of the New York
Aca,demy of Science 121, 321 and 404; 2.5 milliamp per tube, 1.5
; hours running time) it gives a single coomasie blue staining
7~ b~
b~ about 5 mm from the top of the gel which was about 5 cm in
length.
The material does not contain detectable lipoprotein
by Fat Red 7B staining (Corning Fat Red 7B Stain Set, Catalog
No. 470126, July, 1974 instruction sheet, Corning ACI 490 San
Antonio Road, Palo Alto, Calif. 94300).
Additionally, it is apparently free of glycoprotein
when tested with Alcian Blue stain following the procedure des-
cribed in Analytical Biochemistry 49, 607, 1972).
~'............. '
'1
, .
:, .
-- 11 --

Representative Drawing

Sorry, the representative drawing for patent document number 1049405 was not found.

Administrative Status

2024-08-01:As part of the Next Generation Patents (NGP) transition, the Canadian Patents Database (CPD) now contains a more detailed Event History, which replicates the Event Log of our new back-office solution.

Please note that "Inactive:" events refers to events no longer in use in our new back-office solution.

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Event History , Maintenance Fee  and Payment History  should be consulted.

Event History

Description Date
Inactive: IPC from MCD 2006-03-11
Inactive: Expired (old Act Patent) latest possible expiry date 1996-02-27
Grant by Issuance 1979-02-27

Abandonment History

There is no abandonment history.

Owners on Record

Note: Records showing the ownership history in alphabetical order.

Current Owners on Record
EMANUEL SILVERSTEIN
Past Owners on Record
None
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.
Documents

To view selected files, please enter reCAPTCHA code :



To view images, click a link in the Document Description column. To download the documents, select one or more checkboxes in the first column and then click the "Download Selected in PDF format (Zip Archive)" or the "Download Selected as Single PDF" button.

List of published and non-published patent-specific documents on the CPD .

If you have any difficulty accessing content, you can call the Client Service Centre at 1-866-997-1936 or send them an e-mail at CIPO Client Service Centre.


Document
Description 
Date
(yyyy-mm-dd) 
Number of pages   Size of Image (KB) 
Cover Page 1994-04-19 1 28
Abstract 1994-04-19 1 24
Claims 1994-04-19 3 96
Drawings 1994-04-19 1 14
Descriptions 1994-04-19 12 521